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ABSTRACT
Clinical rationale for the study. Autonomic nervous system (ANS) involvement in different parkinsonian syndromes has been 
frequently discussed. It is well established in multiple system atrophy (MSA), whereas it is less evident in progressive supranuc-
lear palsy (PSP).
Aims of the study. The aims were to assess the presence and pattern of ANS involvement in MSA and PSP using noninvasive 
tests i.e. the sympathetic skin response (SSR) test and the R-R interval variation (RRIV) test; to analyse the relationship between 
clinical and electrophysiological abnormalities in both disorders; and to assess whether an autonomic profile might help to 
differentiate them. 
Materials and methods. Clinical and electrophysiological assessments of dysautonomia were performed in 59 patients with 
MSA (24 cases of MSA-C and 35 cases of MSA-P), these 59 cases including 31 females, mean disease duration 4.2 ± 2.7 years, 
mean age 60.3 ± 8.4 years, and in 37 patients with PSP (12 females, mean disease duration 4.6 ± 3.6 years, mean age 67.5 ± 6.1 
years) and the results were compared to the results obtained from 23 healthy controls matched for age and sex.
Results. Clinical dysautonomia assessed by an Autonomic Symptoms Questionnaire was observed in 97% of the MSA patients 
and in 84% of the PSP patients. SSR was abnormal in 64% and RRIV was abnormal in 73% of MSA cases. In PSP cases, these figures 
were 78% and 81% respectively. Dysautonomia was clinically more pronounced in MSA compared to PSP (p < 0.05), whereas 
electrophysiological testing revealed frequently subclinical ANS damage in PSP patients.
Conclusions and clinical implications. Our results point to the complementary role of electrophysiological tests in the diag-
nostic work-up of dysautonomia in parkinsonian syndromes.
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Introduction
Although generally believed to be uncommon, in fact 
autonomic disorders are ubiquitous in neurological disease, 
including movement disorders [1].
Sympathetic skin response (SSR) is a relatively simple 
electrophysiological test used in clinical practice to assess the 
reflex activity of sympathetic sudomotor pathways [2–5], and 
is employed to evaluate pre- and postganglionic sympathetic 
activity [2, 3]. SSR has been used to assess ANS function 
in various peripheral and central neurological disorders 
[2, 4, 6]. On the other hand, R-R interval variability (RRIV) 
reflects the state of parasympathetic innervation of the heart 
[6], and gives an insight into sympathovagal tone [7]. Cyclic 
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deep breathing is the best validated stimulus; both afferent 
and efferent pathways are vagally mediated and inhibited by 
anticholinergic agents [1].
MSA is a rare and fatal neurodegenerative disorder that 
is characterised by a variable combination of parkinsonism, 
cerebellar impairment, and autonomic dysfunction [8]. PSP 
is also a neurodegenerative disorder with early postural in-
stability and falls, vertical supranuclear gaze palsy, akinetic-
-rigid predominant and typically symmetric parkinsonism 
with poor response to levodopa, pseudobulbar palsy, and 
frontal release signs [9–12]. Nowadays, PSP can be divided 
into PSP-parkinsonism (PSP-P), PSP-Richardson’s syn-
drome (PSP-RS) and into several other clinical subtypes 
[13], while MSA can be classified as either MSA-cerebellar 
(MSA-C), or MSA-parkinsonism (MSA-P) [14]. Diagnostic 
criteria have been proposed for the clinical diagnosis of 
PSP and MSA [10, 14, 15]. However, pathological brain 
examination post mortem remains the gold standard for 
diagnostic classification. The mean survival rate in patients 
with PSP has been estimated to be 6–7 years [9, 16]; in 
patients with MSA it is 6–10 years [17–19]. According to 
recent research in MSA, severe dysautonomia and the early 
development of combined autonomic and motor features 
are unfavourable predictors of survival [20]. In PSP, early 
dysphagia, cognitive symptoms, PSP-RS phenotype and 
urinary incontinence have been found to be highly pre-
dictive of shorter survival in some studies [10, 11, 16, 20, 
21], whereas sleep disturbances and possible hallucinations 
have been suggested in another study [22].
It is well established that pronounced autonomic failu-
re appears early in MSA, whereas it is less evident in PSP 
[23–26]. The objectives of our study were: to evaluate the 
presence and pattern of ANS involvement in MSA and PSP 
using two noninvasive electrophysiological tests (SSR and 
RRIV); to analyse the relationship between clinical and elec-
trophysiological abnormalities in both disorders; and to assess 
whether an autonomic profile might help to differentiate them.
Materials and methods
Patients
Clinical and electrophysiological assessments of dysau-
tonomia were performed in 59 patients with MSA: 24 with 
a diagnosis of MSA-C [15 men (62.5%)] and 35 with a diag-
nosis of MSA-P [22 women (62.9%)], and in 37 patients with 
PSP (with classical Richardson’s syndrome phenotype). The 
MSA and PSP diagnosis was probable in 48 (81.4%) and 
31 patients (83.8%) respectively. In the rest of the patients, 
the diagnosis was possible. The mean age in the MSA group 
was 60.3 ± 8.4 years (range 40–79), and in the PSP group it 
was 67.5 ± 6.1 years (range 58–80). The mean disease dura-
tion was 4.2 ± 2.7 years (range 1–14) in the MSA group, and 
4.6 ± 3.6 years (range 1–20) in the PSP group. In the MSA 
group, 31 patients (52.5%) were treated with L-dopa (mean 
dose 861 ± 391 mg daily; range 200–1,800 mg) while in the 
PSP group 28 patients (75.7%) received this treatment with 
a mean dose of 804 ± 304 mg (range: 300–1,600). The mean 
age in the MSA-C group was 59.0 ± 7.8 years (range 49–79), 
and in the MSA-P group it was 61.3 ± 8.8 years (range 40–78). 
Patients with the presence of focal cerebral lesions in CT or 
MRI scans and other neurological or previously diagnosed 
severe systemic disorders (such as arterial hypertension or 
diabetes mellitus) or who were taking anticholinergic drugs, 
neuroleptics or drugs known to markedly influence autonomic 
functions (high doses of beta-blockers etc.), or with a history of 
alcohol or drug abuse were excluded from the study [27]. The 
control group consisted of 23 volunteers [16 women (69.6%)] 
with a mean age of 56.6 ± 14.0 years (range 42–91). 
All patients were diagnosed and treated at the Department 
of Neurology, Medical University of Warsaw. The diagnosis 
of MSA was made according to the criteria established by 
Gilman et al. [14] and PSP according to the National Institute 
for Neurological Diseases and Stroke and The Society for PSP 
(NINDS-SPSP) [10] by movement disorders specialists (APCh, 
PJ, ZJ) based on a detailed history and a neurological examina-
tion. Antiparkinsonian treatment (mostly L-dopa medication) 
was not interrupted before examination, but the last dose was 
taken at least 24 hours before the examination took place. 
Methods
Electrophysiological studies and clinical evaluations were 
performed at the Evoked Potential and Autonomic System La-
boratory of the Department of Neurology, Medical University 
of Warsaw, between 2008 and 2015. All patients and controls 
gave informed consent to the protocol (for electrophysiolo-
gical tests and clinical evaluation). The study protocol was 
reviewed and approved by the Bioethical Committee at the 
Medical University of Warsaw (No AKBE 13/2006). All the 
procedures were in accord with the standards of the Commit-
tee on Human Experimentation of the Medical University of 
Warsaw, and with the Helsinki Declaration of 1975. 
Clinical evaluation
The clinical evaluation of dysautonomia was performed by 
two independent physicians (MN and BZP) on the same day 
as RRIV and SSR tests. We assessed the incidence and distri-
bution of symptoms of dysautonomia as well as their intensity. 
We modified the Autonomic Symptoms Questionnaire pro-
posed by Low [28] to evaluate the intensity of dysautonomia 
semiquantitatively using an arbitrarily defined score system 
(0 points — no symptoms; 1 point — symptoms present. 
Orthostatic hypotension was defined as a blood pressure 
decrease of 30 mmHg systolic or 15 mmHg diastolic within 
three minutes after standing up from a recumbent position 
according to MSA criteria [8]: 0 points — no symptoms; 
1 point — mild  → symptoms present only when there were 
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facilitating conditions; 2 points — severe → symptoms present 
at all times, disabling).
Electrophysiological tests
SSR and RRIV tests were recorded in subjects lying in 
a semi-darkened room, with a temperature of 22—26°C, 
after having relaxed for several minutes. Tests were recorded 
at the same time of day (between 10.00 and 13.00), within 
a few hours after a light meal using the Viking IV, Nicolet 
Biomedical Inc. (Multi-Mode Program Plus, version 4.0). Both 
tests were performed according to a protocol recommended 
by IFCN and described earlier [27]. The frequency of breaths 
during deep breathing was six per minute. The normal values 
were not corrected for age.
SSR
The latency and amplitude (peak to peak) of the highest 
response were measured (five evoked responses were registe-
red, but only the one of the shortest latency was analysed). 
The SSR was considered abnormal if the latency was longer 
by more than two standard deviations (SDs) than that of the 
control group, or if a response was absent (i.e. not elicited by 
three consecutive stimulations). Additionally, we evaluated 
the degree of SSR abnormality using a five-level scale created 
in our Laboratory: 0 points — normal response; 1 point — 
increased latency in one limb; 2 points — increased latency 
in both limbs or the absence of a response from one limb; 
3 points — increased latency in one limb and the absence 
of a response from the other limb; 4 points — absence of 
response from both limbs. 
RRIV
The RRIV result was considered abnormal if we registered 
decreased RRIV at rest or during deep breathing, or if no 
increase of the RRIV during deep breathing could be observed. 
Additionally, we evaluated the degree of RRIV abnormality 
using a three-level scale created in our Laboratory: 0 points — 
normal RRIV test at rest AND during deep breathing AND an 
increase of the RRIV during deep breathing; 1 point — abnor-
mal (decreased) RRIV test at rest OR during deep breathing 
OR no increase of the RRIV during deep breathing; 2 points 
— abnormal (decreased) RRIV test at rest AND during deep 
breathing AND no increase of the RRIV during deep breathing. 
Combined electrophysiological score
A combined electrophysiological score, with values ran-
ging from 0 to 6, was created by combining the results from 
our SSR and RRIV scores.
Statistical analysis
Prior to analysis, the normality of distribution of the 
functional variables was tested by Shapiro-Wilk test. Where 
non-normal distribution was found, correlations analysis 
between different parameters was performed using Spearman’s 
correlation coefficients test. For group comparison, Wilcoxon 
rank-sum, Chi-square and Fisher exact tests were used. Stati-
stical significance was defined as p < 0.05. Values are presented 
as mean ± SD. As an additional analysis, logistic regression 
was used to calculate the significance level because of the 
presence of confounding factors such as age and gender (in 
some group comparisons).
Results
The demographic profile of the two studied groups diffe-
red significantly: patients in the PSP group were older than 
patients in the MSA group (p < 0.001), and the majority of 
them were male (67.6% in the PSP group vs 47.5% in the MSA 
group; NS). This difference was more clearly seen when the 
PSP group was compared to the MSA-P group which contai-
ned only 13 men (31.1%, p < 0.05). The control group was 
matched for age and sex to the MSA group, but there were 
statistically significant differences between the control group 
and the PSP group. Volunteers were younger (p = 0.001), and 
the majority of them were female (p = 0.005). 
Clinical evaluation
Clinical symptoms of dysautonomia were found in 96.6% 
(57/59) of our MSA patients and in 83.8% (31/37) of PSP pa-
tients. The distribution of symptoms differed significantly be-
tween these groups, especially when orthostatic hypotension, 
dizziness and urinary incontinence were evaluated (Tab. 1).
When the MSA group was divided into MSA-P and MSA-
-C subgroups, orthostatic hypotension, urinary incontinence 
and constipation were significantly more often reported in 
the former. We did not find significant differences between 
MSA-C and PSP, although comparing PSP to MSA-P we 
found statistically significant differences in the frequency of 
all symptoms, except for urinary retention and constipation.
In semiquantitative evaluation of the intensity of 
dysautonomia, the mean score was higher in the MSA 
group as a whole (3.4 ± 1.8 points) than in the PSP group 
(2.7 ± 1.8 points), but this tendency did not reach statistical 
significance (p = 0.054). When compared to PSP only, the 
MSA-P subgroup (mean 3.9 ± 1.7 points) results differed 
significantly. The intensity of clinical symptoms of dysau-
tonomia was also more severe in the MSA-P subgroup than 
in the MSA-C (mean 2.7 ± 1.7 points) subgroup (p < 0.05). 
Electrophysiological tests
SSR
The mean values of SSR from upper and lower limbs in 
controls, MSA and PSP patients are presented in Table 2. 
Technical reasons meant that we could not evaluate SSR 
results in three patients from each patient group.
The mean values of SSR latency in MSA and PSP patients 
were significantly higher than in controls for both the upper 
and lower limbs.
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In only 21 (35.6%) patients with MSA and in eight (21.6%) 
patients with PSP, the SSR results were within normal limits. 
In 11 (18.6%) patients in the MSA group, a response was 
not registered in the upper limbs, and in 20 (33.9%) patients 
a response was not registered in the lower limbs. These chan-
ges in the upper limbs were more pronounced in the MSA-P 
subgroup than in the MSA-C subgroup (22.9% vs 12.5% 
respectively). In the PSP group, SSR was not registered in the 
upper limbs in 13 (35.4%) patients and in the lower limbs in 
21 (56.8%) patients. The differences between the MSA and 
PSP groups were statistically significant (for both the upper 
and lower limbs).  
The distribution of SSR abnormalities (in scores) in MSA 
and PSP patients is shown in Figure 1a. 
RRIV
The mean values of RRIV response at rest and during deep 
breathing in controls, MSA and PSP patients are presented in 
Table 2. Technical reasons meant we could not evaluate RRIV 
results in five patients from each patient group.
All mean values of RRIV parameters in MSA and PSP 
patients were significantly lower than in controls. 
Most of the patients reached the highest score of 2 points 
on our scale of RRIV changes intensity, with the highest rate 
in the MSA-P subgroup (51.4%). Only in 16 (27.1%) patients 
with MSA and in seven (18.9%) patients with PSP were the 
results of RRIV normal (Fig. 1b). 
Combined electrophysiological score
A combined electrophysiological score could be obtained 
in 51 MSA and 30 PSP patients. Only in eight (15.7%) patients 
with MSA [three (15.0%) with MSA-C and five (16.1%) with 
MSA-P] and in two (6.7%) patients with PSP were the results 
of both tests (SSR and RRIV) within normal limits. In the MSA 
patients, the intensity of change most frequently seen (29.4%) 
was ‘mild’ (a score of 2). On the other hand, in the PSP group 
‘severe’ changes (a score of 6) were found most often (30.0%) 
but only in 9.8% of patients in the MSA group, although this 
tendency did not reach statistical significance (p = 0.057) 
(Fig. 1c). Within the MSA group there was a tendency to 
Table 1. Frequency of symptoms of dysautonomia in MSA (n = 59) and PSP (n = 37) groups in Autonomic Symptoms Questionnaire for semiquantitative eva-
luation of dysautonomia. Modified from Low, 1997
Symptom of dysautonomia MSA group 
No of patients (%)
PSP group 
No of patients (%)
P value*
Orthostatic hypotension
mild
severe
41 (69.5)
16 (39)
25 (61)
19 (51.4)
12 (63.2) 
7 (36.8)
P < 0.05
Urinary incontinence 40 (67.8) 17 (45.9) P < 0.05
Urinary retention 18 (30.5) 15 (40.5) NS
Impotence (in men) 15 (53.6) 12 (48) NS
Dizziness 22 (37.3) 5 (13.5) P < 0.05
Syncope 20 (33.9) 8 (21.6) NS
Constipation 19 (32.2) 15 (40.5) NS
*P < 0.05 Chi square test; NS — not statistically significant
Table 2. Latency of SSR test (in upper and lower limbs) and RRIV test results (at rest and during deep breathing) in MSA (n = 59) and PSP (n = 37) patients and 
control group (n = 23)
SSR latency (sec)  
mean ± SD (range)
RRIV test results (%) 
mean ± SD (range)
upper limb lower limb R mean R–DB
MSA 1.58 ± 0.3*
(1.04–2.42)
2.11 ± 0.3*
(1.45–2.92)
7.26 ± 4.42**
(2.31–27.0)
14.41 ± 7.88**
(2.75–36.85)
PSP 1.63 ± 0.24*
(1.24–2.34)
2.12 ± 0.3*
(1.68–2.97)
5.78 ± 2.23**
(1.93–10.98)
12.19 ± 6.84**
(2.26–29.40)
Control group 1.37 ± 0.12
(1.12–1.60)
1.89 ± 0.23
(1.49–2.29)
11.96 ± 5.36
(4.96–24.07)
29.86 ± 16.53
(8.40–61.40)
MSA — multiple system atrophy; PSP — progressive supranuclear palsy; R mean — mean HRV at rest; R-DB — HRV during deep breathing; RRIV — R-R interval variation test; sec — seconds; SD — standard 
deviation; SSR — sympathetic skin response; *statistically significant changes compared to control group (p < 0.05, using t-Test); **statistically significant changes compared to control group (p < 0.05, using 
Wilcoxon test) 
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more severe changes (scores 5 and 6) in the MSA-P subgroup 
compared to MSA-C patients. 
We found a mild, but significant, correlation between 
the results of SSR and RRIV tests in the PSP group (r = 0.38; 
p < 0.05). In the MSA group as a whole, as well as after division 
into subgroups, we found no such correlation. 
Correlation between clinical and electrophysio-
logical assessments of dysautonomia 
The relationship between the presence and degree of 
electrophysiological changes (SSR and RRIV scores evalu-
ated together and separately) and the intensity of clinical 
symptoms in the groups of patients with MSA and PSP 
were also analysed. In the MSA group, we found statistically 
significant correlations between clinical symptom score and 
SSR score as well as with the combined electrophysiological 
score (both r = 0.44; p < 0.001). An even stronger correlation 
was found in the MSA-P subgroup (r = 0.57 and r = 0.56 re-
spectively; p < 0.001). In PSP and MSA-C patients, no such 
correlation was found. No relationship between age, duration 
of disease and the values of the parameters analysed in the SSR 
and RRIV tests was revealed by a Spearman correlation test.
Discussion
Dysautonomia is common in parkinsonian syndromes 
affecting a wide spectrum of domains. It is well established 
that pronounced autonomic failure appears early in MSA, 
whereas it is less evident in PSP [23–26, 29]. 
In our study nearly 97% patients with MSA and 84% with 
PSP presented clinical signs of dysautonomia and they could 
be seen most frequently in the MSA-P subgroup. Our results 
are consistent with previous studies of MSA, where early and 
severe autonomic failure with predominant involvement of 
urinary and cardiovascular domains has been described as 
a key feature of the disease [19, 30–33]. The ANS involvement 
in PSP is not so clearly established. 
In our study the intensity of symptoms in PSP in most 
cases was mild. In some reviews, constipation and urinary 
incontinence have been described as the most prevalent 
non-motor features of PSP, especially in the late stages of 
the disease [22]. Other studies have noted orthostatic hypo-
tension, dizziness, lack of sweating and sexual dysfunction 
[16, 21, 23, 24, 34, 35]. Some authors have emphasised that 
comorbidities such as benign prostatic hypertrophy or medi-
cation use could explain some of these symptoms, because in 
many PSP patients objective evidence of autonomic dysfun-
ction could not be found in diagnostic tests [22, 34, 36, 37]. 
There have also been reports that there are no prominent 
autonomic abnormalities in PSP [13, 25, 26, 29, 38], and the 
presence of cardiovascular symptoms has even been proposed 
as an exclusion criterion for PSP [25].
We found abnormal SSR results in 59% of MSA patients 
and in 70% of patients with PSP. The pattern of involvement 
was distinct in both disorders, and those differences were 
statistically significant. The degree of SSR abnormalities was 
greater in the PSP than in the MSA group, and greater in the 
MSA-P than in the MSA-C subgroup. 
Many studies have reported abnormalities in SSR results 
in 69%, and even up to 100%, of MSA patients [7, 35, 40–44]. 
Bordet et al. calculated the sensitivity of SSR examination in 
MSA diagnosis as 0.69 and the specificity as 0.92 [7]. On the 
other hand, Reimann et al. did not find differences in SSR re-
sults between MSA, PSP and PD groups [43], but they evoked 
SSR using acoustic stimulation. They also included in their 
study patients with significant comorbidities known to affect 
Figure 1. Distribution of intensity of SSR (1a) and RRIV (1b) abnor-
malities (in scores) and results in combined electrophysiological 
score (1c) in MSA (n = 59) and PSP patients (n = 37). MSA — 
multiple system atrophy; PSP — progressive supranuclear palsy; 
RRIV — R-R interval variation test; sec — seconds; SD — standard 
deviation; SSR — sympathetic skin response
A
B
C
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ANS function such as diabetes mellitus. The differences with 
our results could be caused by the SSR protocol applied. We 
used electrical stimulus to evoke SSR, because some of our 
patients with parkinsonism poorly cooperated during exami-
nation. This type of stimulus is easier to standardise in patients 
with central nervous system disorders [7, 39, 40] and has 
been found to provide the most reproducible responses [5].
SSR involves both the pre- and postganglionic sympathe-
tic systems [2, 3, 6 ].The preganglionic efferent pathway is ma-
inly the output of the intermediolateral column (ILC) of the 
spinal cord, which is frequently involved in the pathological 
process in MSA [19]. Such a central lesion might be the main 
determinant of abnormal SSR, as opposed to postganglionic 
dysfunction which can be seen for example in PD [7, 45]. 
Reports assessing SSR in patients with PSP and PD have 
shown that sudomotor function was markedly more involved 
in the former [46]. Pressor responses induced by emotional 
or physical stimuli or mental stress have also been reported 
to be diminished in PSP [25, 35]. This type of sweating on the 
palms and soles is independent of the ambient temperature 
(so-called ‘emotional sweating’) and is regulated by the limbic 
system, motor system and reticular formation [35]. Many of 
these structures are known to be frequently affected by the 
neurodegenerative process in PSP [7, 12, 22, 48]. Hence, 
similarly to MSA, sympathetic dysfunction in PSP may also 
be classified as of central, preganglionic origin.
There is also the possibility that the lack of SSR could be 
attributed to age. Drory and Korczyn reported that SSR could 
not been evoked in the hand in 27% of normal subjects above 
60 years of age [39]. On the other hand however, Hay et al. 
reported the presence of responses in all elderly subjects [47]. 
Although there was a significant age difference between PSP 
patients and the control group in our study, a logistic model of 
analysis additionally proved that the differences in SSR results 
between both groups were independent of age. 
We found abnormal RRIV results in 64% of patients with 
MSA and in nearly 68% of PSP patients, and in most cases 
the intensity of changes was severe.
Previous reports have described a lower mean value of he-
art rate variation (HRV) especially after deep breathing in over 
60% of patients with MSA [7, 29, 40]. Pathological results have 
been found at all ages and within a short disease duration. 
However, other results did not confirm these findings [49].
Besides ILC, many ANS structures are affected by neuro-
degenerative changes in MSA, including dorsal vagal motor 
nucleus [19], which seems to be responsible for RRIV changes 
in MSA [7]. Because RRIV reflects the sympathovagal balance, 
so impairment in the sympathetic part of ANS reflected by 
SSR abnormalities might also contribute to RRIV changes [7]. 
Contrary to our results, previous reports have shown 
no remarkable changes in HRV in PSP [23, 25]. In the study 
conducted by Kikkawa et al. the mean HRV value at rest was 
lower in PSP than in the control group [35]. Holmberg et al. 
found only in four out of 14 patients with PSP decreased HRV 
during controlled deep breathing and limited hypotensive 
response during orthostatic provocation. In most cases (64%), 
the results of both tests did not differ from controls [29].
Tau pathology in PSP is widely distributed in the brain, 
resulting in damage to various pathways [12, 13]. It has been 
hypothesised that different PSP disease phenotypes might 
emerge from the preferential spread of tau through different 
brain networks that are functionally and neuroanatomically 
connected [13]. Therefore, we cannot exclude that in some 
patients neuropathological changes can spread and involve 
directly the parasympathetic structures responsible for RRIV 
changes in PSP. On the other hand, the involvement of sites 
important for the sympathovagal balance might also con-
tribute to the RRIV changes seen in our patients with PSP.
Only in 16% of MSA patients and in 7% of PSP patients 
were the results of both electrophysiological tests within 
normal limits. The changes in laboratory tests were more 
pronounced in the PSP patients than in the MSA patients, but 
their distribution was not significantly different. We found 
a statistically significant correlation between the intensity 
of clinical symptoms of dysautonomia and the combined 
electrophysiological score in MSA patients, especially in the 
MSA-P subgroup. Other studies have found no such corre-
lation in MSA [40].
Clinical implications  
and future directions
In parkinsonian syndromes, especially in MSA, a different 
degree of autonomic failure occurs that might significantly 
impair a patient’s quality of life [12, 19, 20, 22, 31, 50]. The-
refore a systematic investigation of dysautonomia has been 
proposed as a relevant diagnostic assessment in parkinsonian 
syndromes [7, 33, 35, 40–42]. 
According to our results, sympathetic and parasym-
pathetic involvement occurs in both MSA and PSP, but the 
intensity of changes varies between these two disorders and 
can be assessed by non-invasive electrophysiological tests. In 
MSA, a significant correlation between the intensity of clinical 
symptoms of dysautonomia and electrophysiological tests 
results can be found, whereas abnormal results of electrop-
hysiological tests without clinical evidence of dysautonomia 
is more suggestive of PSP. 
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